Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis
 (SSc) and at least one calcinotic lesion of the hands that is palpable on physical
 examination and also measureable on hand radiographs, at one single center. Each subject will
 receive treprostinil orally for 12 months, and follow-up evaluations will be performed every
 3 months. Our main objective is to determine whether oral treprostinil is safe, and effective
 in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of
 microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial
 in the treatment of calcinosis in patients with SSc.
1. Background:

 Calcinosis cutis is the deposition of calcium in the skin and subcutaneous tissues. It
 is a common and potentially debilitating manifestation of systemic sclerosis (SSc),
 affecting almost one quarter of these patients. Several studies have found an
 association between calcinosis and vascular manifestations of SSc including digital
 ulcers (DU), and acro-osteolysis. The investigators confirmed this in a retrospective
 multi-center international cohort study of 5280 patients with SSc where DUs were the
 strongest predictor of calcinosis in multivariate analysis (OR 3.7, 95%CI 2.6-5.3,
 p<0.0001).

 Treprostinil delivered by continuous subcutaneous infusion was effective in both the
 healing and prevention of DU in patients with SSc in an open-label, single-center
 clinical trial of 5 (of 12) patients who were able to tolerate the medication. A study
 of 148 subjects with DU showed that the administration of oral treprostinil up to 16 mg
 twice daily for 20 weeks was associated with a small but statistically insignificant
 reduction in net ulcer burden in comparison to placebo. Additionally, preliminary
 observations in the Pulmonary Hypertension Assessment and Recognition of Outcomes in
 Scleroderma (PHAROS) registry have found that two patients with SSc-PAH and calcinosis
 treated with subcutaneous treprostinil for PAH experienced approximately 50%
 radiographic improvement in their calcinosis lesions after 6 months of therapy.

 The investigators developed and validated a novel radiographic scoring system to assess
 the severity of calcinosis affecting the hands of patients with SSc that accounts for
 area coverage, density, and anatomic location. This scoring system is feasible and was
 found to have excellent intra- and inter-rater reliability with intra-class correlation
 coefficients (ICC) of .93 (.89-.97) and .89 (.86-.92), respectively.

 Given that calcinosis is a frequent, debilitating complication of SSc associated with
 digital vascular ischemia with no effective therapies, a clinical trial, using novel
 outcome measures, testing the safety and efficacy of a powerful vasodilator for the
 treatment of calcinosis is warranted.

 2. Primary/Secondary objectives:

 Our main objective is to conduct an open-label proof-of-concept study with the primary
 and secondary endpoints entered elsewhere.

 3. Hypothesis:

 The investigators hypothesize that calcinosis is a result of microvascular injury and
 ischemic damage, and that therefore treprostinil may be beneficial in the treatment of
 calcinosis in patients with SSc.

 4. Study design:

 This prospective open-label trial will enroll 12 patients with SSc and at least one
 calcinotic lesion of the hands that is palpable on physical examination and also
 measureable on hand radiographs. Each subject will undergo a screening evaluation 4
 weeks before treatment with the study drug is initiated. Each subject will receive
 treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4
 days as tolerated. Follow-up evaluations will be performed every 3 months over a
 12-month period of time.

 5. Study population:

 The population for this study will consist of adult SSc patients with evidence of at
 least one calcinotic lesion of the hands that is palpable on physical examination and
 also measureable on hand radiographs. Inclusion and exclusion criteria have been entered
 elsewhere.

 6. Description of the treatment:

 United Therapeutics will provide treprostinil labeled for investigational use. The
 Sponsor/Investigator of the trial will ensure maintenance of complete and accurate
 records of the receipt, dispensation, and disposal or return of all trial drug in
 accordance with Title 21 Code of Federal Regulations (C.F.R.), Part 312.57 and 312.62
 and United Therapeutics requirements.

 Treprostinil Treprostinil (Orenitram) is a prostacyclin vasodilator indicated for the
 treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
 The molecular formula is C23H34O5C4H11NO2, and its molecular weight is 495.65. Orenitram
 is an extended release osmotic tablet for oral administration, and it is formulated as
 the diolamine salt of treprostinil, a tricyclic benzindene analogue of prostacyclin. It
 is available in the following four strengths: 0.125 mg (white tablet imprinted with UT
 0.125), 0.25 mg (green tablet imprinted with UT 0.25), 1 mg (yellow tablet imprinted
 with UT 1), and 2.5 mg (pink tablet imprinted with UT 2.5). The formulations also
 contain xylitol, maltodextrin, sodium lauryl sulfate, magnesium stearate, cellulose
 acetate, triethyl citrate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and
 talc. In addition tablets may contain colorants FD&C Blue 2, iron oxide yellow, and iron
 oxide red. The imprinting ink contains shellac glaze, ethanol, isopropyl alcohol USP,
 iron oxide black, n-butyl alcohol, propylene glycol, and ammonium hydroxide.

 Mechanism of Action The major pharmacologic actions of treprostinil are direct
 vasodilation of pulmonary and systemic arterial vascular beds, inhibition of platelet
 aggregation, and inhibition of smooth muscle cell proliferation.

 Storage Treprostinil must be stored at 25°C (77°F); excursions 15°C to 30°C (59°F to
 86°F). For further details, see the Investigator Brochure and the Orenitram Package
 Insert.

 Dosage and Administration Initiate treprostinil at 0.125 mg TID (every 8 ± 2 h), with
 dose escalation of an additional 0.125 mg TID every 3 to 4 days as tolerated. No dose
 changes will be allowed for 5 days before the month 12 visit. Give with food, swallow
 tablets whole, and use only intact tablets; do not crush, split, or chew. The maximum
 dose, dose escalation or titration will be done at the Investigator's discretion based
 upon individual subject tolerability. Patients with mild hepatic impairment (Child Pugh
 Class A) should initiate treprostinil at 0.125 mg TID, and increment at 0.125 mg TID
 every 6 to 8 days.[8]

 Criteria for Treatment Discontinuation

 Treatment will be discontinued in the following circumstances:

 -  Patients who wish to withdraw from further participation

 -  Patients with a serious or life-threatening adverse event that in the opinion of
 the investigator is directly attributable to the study drug

 -  The patient deviated from the protocol

 -  The patient's behavior is likely to undermine the validity of his / her results

 -  Patients who have a positive pregnancy test during the study

 -  Patients who develop any condition that in the opinion of the investigator could be
 worsened by further treatment with the study drug

 Criteria for Stopping Rules The study may be stopped at any time if, in the opinion of
 the Investigator and / or Sponsor, continuation of the study represents a serious
 medical risk to the subjects. This may include, but is not limited to, the presence of
 serious, life-threatening, or fatal adverse events or adverse events that are
 unacceptable in nature, severity, or frequency. The Sponsor reserves the right to
 discontinue the study for any reason at any time.

 7. Estimated duration: 12 months

 8. Time and events schedule and description of assessments:

 What will happen at each visit?

 Screening Visit (1 month prior to treatment):

 -  Informed consent

 -  Review of inclusion and exclusion criteria

 -  Complete medical history including scleroderma diagnosis

 -  Review of concomitant medications

 -  Complete physical examination including examination of calcinosis, digital ulcers,
 vital signs, height/weight, and Modified Rodnan skin score (MRSS)

 -  Electrocardiogram (EKG)

 -  Laboratory tests: CBC with differential, comprehensive metabolic panel, and
 urinalysis

 -  Urine pregnancy test (females of child bearing potential only)

 -  Review of adverse events

 Baseline Visit (0 month):

 -  Review of concomitant medications

 -  Complete physical examination with vital signs, and MRSS

 -  Examination of calcinosis and digital ulcers

 -  Laboratory tests: CBC with differential, comprehensive metabolic panel, and
 urinalysis

 -  Urine pregnancy test (females of child bearing potential only)

 -  Questionnaires: SHAQ, Cochin hand functional scale, SF-36 assessment of health
 status, Mawdsley Calcinosis Questionnaire, Physician/Patient Global Assessment of
 calcinosis severity, and Raynaud's Condition Score.

 -  Review of adverse events

 -  Study drug dispense/return

 -  Radiological assessment of calcinosis

 -  Skin biopsy

 -  Blood for biomarker analyses

 -  SPY assessment of superficial blood flow

 -  XtremeCT II scan

 At 3 months visit:

 -  Review of concomitant medications

 -  Examination of calcinosis and digital ulcers

 -  Urine pregnancy test (females of child bearing potential only)

 -  Questionnaires: SHAQ, Cochin hand functional scale, SF-36 assessment of health
 status, Mawdsley Calcinosis Questionnaire, Physician/Patient Global Assessment of
 calcinosis severity, and Raynaud's Condition Score.

 -  Blood for biomarker analyses

 -  Review of adverse events

 -  Study drug dispense/return

 At 6 months visit:

 -  Review of concomitant medications

 -  Examination of calcinosis and digital ulcers

 -  Complete physical examination with vital signs, and MRSS

 -  Laboratory tests: CBC with differential, comprehensive metabolic panel, and
 urinalysis

 -  Urine pregnancy test (females of child bearing potential only)

 -  Questionnaires: SHAQ, Cochin hand functional scale, SF-36 assessment of health
 status, Mawdsley Calcinosis Questionnaire, Physician/Patient Global Assessment of
 calcinosis severity, and Raynaud's Condition Score.

 -  Review of adverse events

 -  Study drug dispense/return

 At 9 months visit:

 -  Review of concomitant medications

 -  Examination of calcinosis and digital ulcers

 -  Urine pregnancy test (females of child bearing potential only)

 -  Questionnaires: SHAQ, Cochin hand functional scale, SF-36 assessment of health
 status, Mawdsley Calcinosis Questionnaire, Physician/Patient Global Assessment of
 calcinosis severity, and Raynaud's Condition Score.

 -  Review of adverse events

 -  Study drug dispense/return

 At 12 months visit:

 -  Review of concomitant medications

 -  Examination of calcinosis and digital ulcers

 -  Urine pregnancy test (females of child bearing potential only)

 -  Questionnaires: SHAQ, Cochin hand functional scale, SF-36 assessment of health
 status, Mawdsley Calcinosis Questionnaire, Physician/Patient Global Assessment of
 calcinosis severity, and Raynaud's Condition Score.

 -  Review of adverse events

 -  Study drug dispense/return

 -  Complete physical examination with vital signs, and MRSS

 -  Laboratory tests: CBC with differential, comprehensive metabolic panel, and
 urinalysis

 -  Radiological assessment of calcinosis

 -  Skin biopsy

 -  Blood for biomarker analyses

 -  SPY assessment of superficial blood flow

 -  EKG

 Description of assessments:

 Medical history including SSc: Significant past or present illnesses, current
 prescription or nonprescription medications (including vitamins and herbal products),
 and history of allergies or idiosyncratic responses to drugs should be noted.

 Physical examination: A complete physical examination will be conducted by a physician
 at Screening, 6 months, and at end of study. Any significant changes to the subject's
 medical condition, physical examination, and concomitant medications should be
 documented throughout the course of the study. Any untoward medical experience should be
 recorded as an adverse event.

 Examination of calcinosis and digital ulcers: Investigator will perform a thorough
 clinical examination looking for calcinotic deposits at each visit. The investigators
 will use case report forms with picture images of the hands to record calcinosis and
 digital ulcers at each evaluation. The investigators will define digital ulcer as an
 area with visually discernable depth and a loss of continuity of epithelial coverage in
 the volar aspect of the finger and distal from the proximal interphalangeal joints,
 which could be denuded (active) or covered by a scab or necrotic tissue (indeterminate).
 At each visit, the status of each digital ulcer will be rated as "A," a current active
 digital ulcer, "H", a completely healed ulcer, or "I," an ulcer with indeterminate
 status, as previously defined.

 Vital Signs: Systolic and diastolic blood pressure, heart rate, respiratory rate, and
 temperature (°C) will be measured prior to assessments and after sitting for 5 minutes
 at screening, baseline, 6 months, and 12 months. Vital signs should also be assessed in
 the case of abnormal clinical signs and symptoms.

 Electrocardiogram (ECG): Twelve-lead ECGs will be recorded after at least 5 minutes rest
 in the semi-recumbent position at screening and at the end of the study at 12 months.
 Recordings should include lead II as a rhythm strip and contain at least 5 QRS
 complexes. ECG parameters collected (after at least 5 minutes rest) include heart rate,
 and PR interval, QT interval, QRS duration and any clinically significant abnormalities.

 Laboratory tests: Blood and urine samples for the measurement and evaluation of CBC,
 CMP, and urinalysis (UA) will be collected at screening, 6 months and at the end of the
 study, and analyzed at Stanford laboratory.

 Urine pregnancy test: urine beta-HCG will be measured in all female in reproductive age
 at all visits.

 Radiological examination of calcinosis: Patients will have plain radiographs of the
 hands at baseline and at 1 year.

 Scleroderma Health Assessment Questionnaire (SHAQ): The SHAQ is a patient
 self-administered instrument, which has been previously validated in SSc and
 demonstrates meaningful clinical changes in the course of the disease over time. It is
 comprised of the HAQ-DI, a self-administered 20-question instrument that assesses a
 patient's level of functional ability and five scleroderma visual analogue scale (VAS)
 measurements to evaluate symptoms specific to SSc.

 Cochin Hand Function Scale (CHFS): CHFS is a questionnaire derived from 18 validated
 questions to assess functional disability and handicap due to hand involvement in
 rheumatoid arthritis. Each answer is scored on a scale of 0 (no difficulty) to 5
 (impossible to do), with a maximum score of 90. A higher score indicates worse
 disability or handicap. The CHFS has been demonstrated as a reliable and valid
 assessment of hand function at the activity level in persons with SSc.

 Mawdsley Calcinosis Questionnaire: The content of this questionnaire is
 patient-generated and includes 17 questions related to the impact of calcinosis rated
 from 0 (no limitation) to 10 (worst limitation possible).

 The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 is one of
 the most widely used instruments to assess quality of life in patients with systemic
 illnesses. It is a self-administered questionnaire covering eight areas: physical
 function, physical role, bodily pain, general health, vitality, social function,
 emotional role, and mental health. For each area, the score ranges from 0 (poorer health
 status) to 100 (better health status).

 Patient and Physician global assessments: Patients and physicians will each
 independently rate the severity of calcinosis on a 10 cm VAS. The term "severity" will
 be used to measure the extent of disease activity and associated disability or
 discomfort the patient experiences during the indicated time period.

 Raynaud's Condition Score (RCS): The investigators will measure changes in Raynaud's
 phenomenon (RP) by using the RCS, a self-assessment of RP activity using a 0-10 ordinal
 scale. The RCS incorporates the cumulative daily frequency, duration, severity, and
 impact of RP attacks.

 Modified Rodnan Skin Score (mRSS): The mRSS measures skin tightness and is the sum of
 scores from 17 surface anatomic areas (fingers, hands, forearms, arms, feet, legs, and
 thighs bilaterally, and face, chest, and abdomen singly) rated on a 0-3 scale (0=normal
 skin; 1=mild thickness; 2=moderate thickness; 3=severe thickness with inability to pinch
 the skin into a fold). The skin score will be the sum of the individual skin assessment
 scores and ranges from 0 (best possible outcome) to 51 (worst possible outcome).

 Skin biopsies: The investigators will collect two side-by-side skin samples to assess
 for vascular changes on histopathology and gene expression changes following treatment
 with treprostinil: one at baseline and one at the end of the study. This part of the
 study will be optional for participating patients. Skin biopsies will be obtained from a
 standard site on the forearm (extensor surface of forearm approximately 10 cm proximal
 to the olecranon, which is chosen for its uniform involvement in patients with SSc). Two
 adjacent 5 mm punch biopsies (taken full thickness to subcutaneous fat) will be
 harvested from the site. This involves selecting an area to biopsy and wiping the skin
 with alcohol. Next, 1-2 cc of lidocaine with 1:100,000 epinephrine is introduced into
 the skin using a 30G needle. Two punch biopsies will then be taken and processed as
 described in appendix I. Next, the wound will be sutured with 1-2 4.0 nylon sutures.
 Wounds will be dressed with polysporin and a bandage. Verbal wound care instructions
 will be given. The first biopsy will be bisected: one half will be flash frozen in
 liquid nitrogen and half will be embedded in paraffin. The second biopsy will also be
 bisected: one half will be placed in RNA later, and the other half will be placed in a
 cryo-tube.

 Research blood: The investigators will collect serum and peripheral blood samples to
 assess changes in vascular and SSc-associated biomarkers following treatment with
 treprostinil. Blood samples for the assessment of biomarkers will be drawn at baseline,
 3 months, and end of study visit. Please see appendix for a complete list of biomarkers.

 SPY: The SPY Near-Infrared Perfusion Assessment System (distributed by LifeCell Corp.,
 Branchburg, N.J.; manufactured by Novadaq Technologies Inc., Richmond, BC, Canada) is an
 imaging technology that utilizes indocyanine green (ICG), and allows real-time visual
 assessment of superficial blood flow.

 XtremeCT II scan: The latest-generation high-resolution peripheral quantitative computed
 tomography (HR-pQCT) XtremeCT II scan is a novel technology with dramatically improved
 spatial resolution. It is able to define the cortical and trabecular surfaces of the
 bones in a three-dimensional fashion, and therefore provides information on bone
 microarchitecture as well as bone density. The XtremeCT II machine at Stanford
 University is one of 10 in the United States.

 Safety: During the study, the primary assessment of safety will be changes in vital
 signs, clinical laboratory parameters, EKG, and the development of adverse events.

 9. Safety monitoring and reporting

 Definitions:

 Adverse Event (AE): An AE is any untoward medical experience occurring to a subject
 during a clinical trial whether or not it is related to the study drug. An AE may
 include an intercurrent illness, injury, or any other concomitant impairment of the
 subject's health, as well as abnormal laboratory findings if deemed to have clinical
 significance. AEs may also include worsening of an existing symptom or condition or
 post-treatment events that occur as a result of protocol-mandated procedures.

 Severe Adverse Event (SAE): A SAE is an AE occurring at any dose that results in any of
 the following outcomes:

 -  Death

 -  A life-threatening AE

 -  Inpatient hospitalization or prolongation of existing hospitalization

 -  A persistent or significant disability / incapacity

 -  A congenital anomaly / birth defect

 In addition, important medical events that may not result in death, be life-threatening,
 or require hospitalization may be considered serious when, based upon appropriate
 medical judgment, they may jeopardize the subject and require medical / surgical
 intervention to prevent one of the outcomes listed above. Examples of such medical
 events include allergic bronchospasm requiring intensive treatment in an emergency room
 or at home, blood dyscrasias or convulsions that do not result in hospitalization, or
 the development of drug dependency or drug abuse. Life threatening means that the
 subject was, in the view of the Investigator, at immediate risk of death from the event
 as it occurred. It does not mean that the event, had it occurred in a more severe form,
 might have caused death.

 Reporting Responsibilities:

 In the event of an adverse event, the first concern will be for the safety of the
 patients.

 Investigators are required to collect and document all adverse events (AEs) and
 non-related serious adverse events (SAEs). All SAEs, regardless of expectedness or
 causality, must be reported to the Sponsor by fax (+ 1 919-313-1297 or other appropriate
 number) within 24 hours of awareness. A completed SAE report form along with any
 relevant hospital records and autopsy reports should be faxed to the Drug Safety
 Department at United Therapeutics Corporation. A follow-up SAE report form must be
 forwarded to the Drug Safety Department at United Therapeutics Corporation within 48
 hours of the receipt of any new / updated information. The Investigator must also
 promptly notify their Investigational Review Board (IRB) or Ethics Committee (EC) of the
 SAE, including any follow-up information, in accordance with applicable national
 regulations and guidelines set forth by the IRB or EC. All documents related to AEs
 (serious, non serious, related, or not) will be readily available for review, should the
 need arise.

 An AE or SAE occurring during the study must be documented in the subject's source
 documents and on the appropriate CRF page. Information relating to the AE such as onset
 and cessation date and times, intensity, seriousness, relationship to study drug, and
 outcome is also to be documented in the CRF. Where possible, AEs should be recorded
 using standard medical terminology. If several signs or symptoms are clearly related to
 a medically defined diagnosis or syndrome, the diagnosis or syndrome should be recorded
 on the CRF page, not the individual signs and symptoms.

 All AEs should be followed until either resolution (or return to normal or baseline
 values), until they are judged by the Investigator to no longer be clinically
 significant, or for at least 4 weeks if the AE extends beyond the final visit. All SAEs
 that occur during the study will be followed until resolution, death, or the subject is
 lost to follow-up even if they are ongoing more than 4 weeks after completion of the
 final visit. Supplemental measurements and / or evaluations may be necessary to
 investigate fully the nature and / or causality of an AE or SAE. This may include
 additional laboratory tests, diagnostic procedures, or consultation with other
 healthcare professionals. CRF pages should be updated.

 10. Statistical Considerations

 Statistical analysis:

 Descriptive statistics and frequency distributions of all variables of interest will be
 reported as proportions (%) for categorical variables and as mean ± standard deviation or
 median (range) for continuous variables. Baseline to 12 month differences and 95% confidence
 intervals will be calculated for scored outcomes (x-ray score, MRSS, physician's global
 assessment by VAS, and quality of life measurements). For the primary efficacy endpoint, mean
 change and standard deviation in calcinosis burden assessed by radiograph from baseline to
 12-month visit, the investigators will use Student's t-test. The mean rate of change of
 calcinosis in radiograph will be calculated with the following formula: (Year 1 XR score -
 Baseline XR score)/time. XR score is defined as: sum of scores for 22 weighted areas
 affecting each hand: %area coverage (0-100) X density (1-3) X weight for each area.

 Sample size calculation:

 The investigators will need 9 paired radiographs (9 patients) at 1-year to provide >80% power
 to detect a mean change in x-ray score of 12.0 (equivalent to a minimally significant change
 in score of 25%) with a SD of 8.2 with moderate correlation r=0.5 using a two-sided test at
 alpha 0.05 level. The investigators estimate a 15% dropout rate based on prior clinical
 trials. Hence, the total number of subjects needed to obtain 9/0.85 subjects who complete the
 study is 11 subjects. Also, due to the small sample size, the investigators plan to use
 Wilcoxon signed rank test to analyze the effects. Thus, the investigators anticipate losing
 about 10% of power due to using a non-parametric test. As a result, the sample size is
 further adjusted to 11/0.9 = 12. Statistical significance will be defined as p ≤ 0.05.
Inclusion Criteria:

 -  Signed written informed consent

 -  Age > 18 years of age

 -  Diagnosis of limited or diffuse cutaneous systemic sclerosis (SSc) according to the
 revised 2013 ACR/EULAR classification criteria for SSc

 -  Radiological and physical examination evidence of at least one subcutaneous calcium
 deposition in the hands that is clinically apparent as part of routine clinical care.

 -  If female of childbearing potential, the patient must have a negative pregnancy test
 at screening and baseline visits

 -  Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are
 permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to screening
 and throughout the study

 -  Calcium channel blockers, alpha-1-antagonists, ACE-inhibitors, angiotensin receptor
 blockers, and protein-pump inhibitors are permitted as long as the doses are stable
 for 4 weeks prior to screening and throughout the study

 -  Women of childbearing potential must agree to use adequate contraception when sexually
 active with any combination of at least 2 effective methods of birth control (except
 for women who have a partner who is sterile, i.e. due to vasectomy)

 Exclusion Criteria:

 -  Rheumatic disease other than SSc

 -  Patients with pulmonary arterial hypertension (PAH), NYHA Class III or IV, as
 determined by right heart catheterization or on PAH approved medications for PAH

 -  Patients with moderate or severe hepatic impairment (Child Pugh Class C), or
 transaminase elevation (ALT or AST) > 3 x the upper limit of normal at screening visit

 -  Patients with diverticulosis

 -  Hemoglobin < 75% of the lower limit of the normal range

 -  Systolic blood pressure < 95 mmHg or diastolic blood pressure < 50 mmHg

 -  Patients who are hemodynamically unstable, or have acute renal, cardiac or pulmonary
 failure, or any life-threatening condition.

 -  Concurrent malignancy except non-melanoma skin cancers

 -  Patients receiving specific (sildenafil, tadalafil) or unspecific phosphodiesterase-5
 inhibitors (dipyridamole, theophylline), endothelin receptor antagonists, prostanoids,
 riociguat, or NO donors (nitrates) within 4 weeks of screening

 -  Patients receiving bisphosphonates, warfarin, colchicine, minocycline, intravenous
 immunoglobulins, or biological agents including abatacept or rituximab within 4 weeks
 of screening

 -  Patients receiving local treatments for calcinosis including surgical removal or
 intralesional steroid injections within 12 weeks of screening or throughout the study.

 -  Patients who have participated in another clinical trial of an investigative agent
 within 30 days of screening (or 5 half-lives of the investigational drug, whichever is
 longer)

 -  Pregnant or nursing women

 -  Patients with a history of drug or alcohol abuse within 6 months of screening

 -  Any medical condition that, in the opinion of the investigator, might interfere with
 the subject's participation in the study or poses an added risk for the subject

 -  Inability to comply with study and follow-up procedures